FDA FINANCIAL DISCLOSURE REG WOULD APPLY TO DATA SUBMITTED UNDER OTC MONOGRAPHS
This article was originally published in The Tan Sheet
FDA FINANCIAL DISCLOSURE REG WOULD APPLY TO DATA SUBMITTED UNDER OTC MONOGRAPHS, the agency stated in a proposed role on "Financial Disclosure by Clinical Investigators," published in the Sept. 22 Federal Register. The disclosure requirements would apply to "clinical data submitted as part of the over-the-counter monograph process," FDA explained, adding that it believes data "submitted for OTC products are no less important than data submitted as part of the NDA or ANDA processes and should be treated similarly." FDA added that it will extend the proposal to foods and animal drugs in a future notice.
You may also be interested in...
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC